Developing a new antibody treatment for advanced lung cancer
Official title: Late-stage development and de-risking of a novel monoclonal antibody immunotherapy for EGFR-positive solid cancers
Funded at Tigatx INC · NIH-10919593 · Data updated 2026-11-12
This study is looking at a new treatment called TIGA-001, which uses a special type of antibody to help your immune system fight advanced lung cancer, and if you're interested, you might have a chance to join future trials to see how well it works.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tigatx INC NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 6, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,418,424 |
| NIH project number | 1R44CA291266-01 |
| Project ID | NIH-10919593 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with advanced or metastatic EGFR-positive non-small cell lung cancer.
✕Less likely to help
Patients with early-stage lung cancer or those without EGFR mutations may not benefit from this research.
What this research studies
This research focuses on creating a novel IgA-based monoclonal antibody, TIGA-001, aimed at treating advanced EGFR-positive non-small cell lung cancer (NSCLC). The approach leverages the body's neutrophils to target and destroy cancer cells more effectively. The research includes extensive laboratory testing to ensure the safety and efficacy of the treatment before it is tested in humans. Patients may have the opportunity to participate in upcoming clinical trials as the research progresses.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that improves survival and quality of life for patients with advanced lung cancer.
How similar studies have gone: Other research has shown promise in using monoclonal antibodies for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
-
Tigatx INC
Boston, United States Active
Researchers
- Principal investigator: Stern, Howard M — Tigatx INC
- Study coordinator: Stern, Howard M
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.